Mark A. Crowther, Jeffrey Ginsberg, Holger Schünemann, Ralph M. Meyer, Richard Lottenberg
John Wiley & Sons, Jan 30, 2009 - Medical - 440 pages
This unique new book uses a series of focussed questions, comprehensive literature evaluations and structured grades of recommendation to provide evidence for the treatment of hematological disorders, both malignant and benign. With contributions from leading international experts who have a real understanding of evidence-based medicine the book provides comprehensive reviews accompanied by clinical commentaries and recommendations on the best treatment regimes to adopt for individual patients.
The book is split into two sections: the first examines the methodology underlying evidence based practice, and the second concentrates on the clinical practice of hematology, providing current “best evidence” to guide practice in a series of well-defined clinical situations.
This clinical reference is an invaluable source of evidence-based information distilled into guidance for clinical practice which will be welcomed by practitioners, trainees and associated health professionals.
What people are saying - Write a review
We haven't found any reviews in the usual places.
ABVD acute myeloid leukemia adults agents allogeneic analysis anemia Ann Intern antibodies anticoagulant therapy anticoagulation assessment associated autologous Blood Cancer chemotherapy chronic Clin Oncol clinical trials compared cyclophosphamide cytarabine D-dimer deep vein thrombosis deferiprone diagnosis disease dose drug effect efficacy evaluated fludarabine follow-up Grade 1C Group guidelines Hematol Hematology heparin high-dose Hodgkin hydroxyurea imatinib included induction initial intravenous iron overload lenalidomide LMWH long-term lymphocytic major bleeding median meta-analysis myeloid leukemia neutropenia non-Hodgkin’s lymphoma oral outcomes overall survival patients receiving pediatric phase platelet platelet count porphyria pregnancy prophylaxis prospective pulmonary embolism quality of evidence randomized controlled trials randomized trials RCTs recommended recurrent VTE regimen relapsed remission reported risk factors rituximab serum splenectomy stem cell transplantation strategy studies surgery syndrome systematic review Table Thromb Haemost thrombocytopenia thrombolytic therapy thrombotic tients toxicity transfusion treatment vena cava filters venous thromboembolism venous thrombosis versus warfarin